WO1998016626A1 - Livestock mucosal competitive exclusion culture to reduce enteropathogenic bacteria - Google Patents
Livestock mucosal competitive exclusion culture to reduce enteropathogenic bacteria Download PDFInfo
- Publication number
- WO1998016626A1 WO1998016626A1 PCT/US1997/018769 US9718769W WO9816626A1 WO 1998016626 A1 WO1998016626 A1 WO 1998016626A1 US 9718769 W US9718769 W US 9718769W WO 9816626 A1 WO9816626 A1 WO 9816626A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- culture
- animal
- administered
- hours
- animals
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Definitions
- This invention relates to a bacterial culture prepared from the intestinal tract of pathogen-free mammalian animals. It also relates to subcultures of such cultures and to methods of using the subcultures to protect livestock from colonization by enteropathogenic bacteria.
- Enteropathogens such as Salmonella and Escherichia coli 0157 :H7, cause an unacceptably high incidence of morbidity and mortality in humans and may reduce productivity in livestock populations.
- Gastrointestinal pathogens in humans are typically derived from intestinal contamination of meats that humans consume.
- a question asked was "How important are foodborne diseases?” (Tracking Foodborne Pathogens from Farm to Table: Data Needs to Evaluate Control Groups, Washington, DC, 3-29, 1995) . It was stated that in the United States, there are an estimated 6.5 million to 33 million cases of foodborne diseases each year, resulting in up to 9,000 deaths.
- CE Competitive exclusion
- Snoeyenbos et al (United States Patent No. 4,335,107, June, 1982) developed a CE micorflora technique for preventing Salmonella colonization by lyophilizing fecal droppings and culturing this preparation anaerobically.
- Mikola et al (United States Patent No. 4,657,762, April, 1987) used intestinal fecal and cecal contents as a source of CE microflora for preventing Salmonella colonization. Treatment with this type of culture required media to be anaerobic and pH balanced.
- Stern et al discloses a mucosal CE composition for protection of poultry against colonization by Salmonella and Campylobactor where the mucin layer of prewashed ceca is scraped and the scrapings, kept in an oxygen-free environment, are cultured anaerobically.
- Nisbet et al (United States Patent No. 5,478,557; December 26, 1996) disclose a probiotic that can be obtained from a variety of domestic animals, including but not limited to fowl and also equine, porcine and bovine.
- Nisbet et al disclose that a stable defined probiotic is preferably obtained by continuous culture of a batch culture produced directly from fecal droppings, cecal and/or large intestine contents of the adult target animal.
- probiotics may be produced by either batch or continuous culture wherein the batch culture is continued until the concentration of acetic acid is greater than or equal to about 20 mM, the concentration of proprionic acid is greater than or equal to about 10 mM and the concentration of butyric plus isobutyric acid is greater than or equal to 15 mM.
- Asplund et al (Journal of Applied Bacteriology, Volume 81, 217-223, 1996) report an in vi tro model of the procine intestine and its use to show inhibiiton of Yersinia enterocoli tica 0:3 by pig ileal and caecal microflora. Caeca and distil parts of the small intestine are collected, kept under anaerobic conditions and the contents collected, pooled and cultivated. Caecal and ileal inocula are shown to suppress the growth of cultured Y. enterolitica, with caecal flora somewhat more effective than ileal flora. No in vivo efficacy was reported.
- the present invention provides for the first time a composition and a method for reducing in vivo and/or preventing colonization of mammals, especially livestock, by enteropathogenic bacteria.
- enteric infections in humans has been increasingly well recognized over the last dozen years.
- the relationship of livestock contamination and human infection has, likewise, become well documented.
- animals such as livestock
- fecal material containing pathogens may be transferred onto meat and persist into food processing kitchens.
- Swine along with poultry, cattle and seafood, are important carriers of Salmonella (Bean et al, J. Food Protect., Volume 53, 804-817, 1990; Lammerding et al, J. Food Protect., Volume 51, 47-52, 1988).
- Naive animals are infected from contaminated feed, chronic carriers which are introduced into the population, infected rodents, or from contaminated farm personnel (Heard, Vet. Rec .
- control means the reduction or prevention of enteropathogenic bacteria colonization.
- food-producing animals means any animal consumed by humans .
- a unique bacterial culture is obtained from the scrapings of the intestinal tract of pathogen-free animals.
- the animals may be of any age, most preferred is the use of young animals, to protect newborn and older animals .
- This initial culture is subcultured and then administered to young animals .
- the method of this invention is applicable to any animal whether domesticated or wild and particularly to livestock raised for human consumption which could serve as a carrier for target pathogens .
- Livestock includes cattle, calves, hogs, pigs, sheep, lambs, buffalo, goats, rabbits, seafood and the like. It is preferred to administer the livestock mucosal competitive exclusion subculture
- the preparation could be administered at any time during the life of the animal such as on a continual basis or at selected times throughout the life span of the animal, for example.
- continuous basis means a consistent source of LMCES is provided by administration through drinking water, feeds, by oral gavage or aerosolization.
- the LMCES can be administered daily in feed or water, weekly, monthly, etc. for the continual basis.
- at selected times throughout the life span of the animal means administration of the LCME culture at critical control points, such as occurs during birth, weaning, disease, antibiotic administration, excessive heat, dehydration, cold, during transport such as movement to other buildings in the production process and prior to transport at slaughter, etc.
- the target pathogens include all human enteropathogenic bacteria capable of colonizing animals, especially livestock raised for human consumption.
- human enteropathogenic bacteria are bacteria capable of or known to colonize the human alimentary canal or disseminating toxins therein, and which are capable of causing intestinal illness in a human host .
- human enteropathogenic bacteria include but are not limited to Salmonella species, Campylobacter species and Escherichia coli .
- the LMCES can be combined with other cultures or treatments effective for the control of Salmonella in animals, such as for example, Lactobacillus, fructooligosaccharides and yeasts. Other conventional or known treatments of animals, and particularly for the inhibition of enteropathogens , may be added to the LMCES as long as they do not affect the activity of the LMCES preparation.
- compositions of livestock mucosal competitive exclusion subcultures are administered to animals.
- administering includes any suitable method for orally delivering the compositions to animals as is known in the art, such as for example by oral gavage, feeding, spraying or applying a paste onto mothers teats or artificial teats, through administered milk etc.
- the LMCES may also be administered through the lower intestinal opening.
- the preparation can be in any form known in the art such as for example, liquid, paste, gel cap or aerosol form for administration.
- the LMCES preparations are administered to animals at any age including new born animals in amounts effective to at least reduce human enteropathogenic bacteria found in the gut of the animals.
- ⁇ a reduction of bacteria' or * at least reduce human enteropathogenic bacteria' refers to a reduction in numbers of bacteria compared to that which would be expected in an animal which did not receive treatment according to the methods of the present invention. Any accurate method of measuring, counting and comparing bacteria present in the intestinal tract of animals may be used for such comparisons, as would be apparent to those skilled in the art.
- LMCES preparation administered, wherein the effect of the administration acts to at least reduce human enteropathogenic bacteria found in all ages of animals.
- the amount of preparation will vary depending on the size of the animal being treated and the method of administration. For small animals, including small new born animals, about 4-8 mis of the second or later passaged 48 hour subculture passage LMCES culture can be administered by oral gavage, with about 5 ml being the preferred dose .
- the second 48 hour subculture passage or later of the LMCES can be undiluted or up to about 10 times diluted for oral administration in a liquid suspension where the diluent can be, for example, milk, water, etc. Additional subculture passages may also be employed but, will likely be less effective. Diluted and undiluted liquid LMCES preparations can be directly administered.
- the LMCES preparation is given within approximately 2-48 hours of birth, with approximately 2-6 hours from birth more preferred, followed by a second dose approximately 18-24 hours later. The most preferred treatment schedule is the first dose within about 6 hours of birth followed by the second dose about 24 hours after birth.
- the first dose of treatment is given about 2 to 48 hours prior to weaning, transport, or movement to other buildings, with a preferred time of about 2-6 hours. In these instances, only one treatment may be required but a second treatment may be administered 18-24 hours after the first treatment. Variations in treatment schedules will reflect commercial husbandry practices. Additional doses may be given at weaning, prior to movement throughout a production facility or prior to transport at slaughter. If given in feed or water, daily administration would occur.
- the LMCES preparation is prepared by aseptically removing the lower intestine including cecum of an animal and placing it in a sterile container.
- lower intestine is defined the portion originating at the end of the stomach through to and including the cecum. This container is kept in an anaerobic environment throughout the preparation of the cultures.
- the selected length of the intestine is inverted by any means known in the art .
- the contents of the intestine are removed by a combination of washing and scraping.
- the washing is done with an appropriate anaerobic medium.
- the washing step may utilize any medium effective for the stated purpose, including water.
- a preferred medium is an anaerobic medium, particularly preferred being a pre-reduced, Eh poised anaerobic medium.
- Superficial scraping is done with a dull edged means, such as for example a dull edged scalpel blade. After the scraping, the lumen is washed again followed by scraping with a sharp edged means such as, for example, the sharp edge of a scalpel or other suitable instrument.
- a dull edged means such as for example a dull edged scalpel blade.
- the sharp edged means and lumen wall are washed with medium, as described above, to obtain epithelial cells and indigenous microflora and the washings are collected in a sterile vessel.
- the tissue can also be cut directly into the culture medium without first scraping. It is preferable to keep the tissue in a reduced atmosphere, i.e. under a stream of nitrogen when the procedure is initiated.
- the wash or cuttings, with associated epithelial cells and microflora are suspended and the contents inoculated into sterile anaerobic medium for culture .
- the term microflora is intended to include indigenous bacteria.
- the culture is incubated anaerobically at about 35-40° C for approximately 48 hours, transferred to fresh anaerobic medium and reincubated for approximately 48 more hours. This second incubation is the second 48 hour subculture passage and is the most preferred LMCES preparation used. Other subculture passages can also be used as described above.
- the culture is then assayed for the presence of human enteropathogens using any appropriate and conventional isolation techniques. Cultures, free of pathogens, are administered immediately, freeze-dried or frozen using conventional techniques for freezing cultured cells . Blood from donor animals should be serologically tested for antibody levels to pertinent host animal, including human, pathogens . Only cultures from animals not seroconverting should be used.
- the intestines of a healthy adult bovine are obtained at a local slaughter establishment and transported in a plastic bag to the laboratory within one hour in a sterile anaerobic environment.
- the mucosal culture is prepared from the lower intestinal tract. Prior to removal of the piece of intestine to be used, the surrounding area is tied off with string to prevent leakage of intestinal contents .
- An approximately 4 to 5 inch length is aseptically removed and placed in a sterile container. The container is then placed into a tub which is continuously being flushed with oxygen-free nitrogen gas. All manipulations are done below the rim of the tub to keep the culture to be harvested in an anaerobic environment .
- the length of the intestinal tissue is carefully inverted on a sterile glass rod without touching the inside surface.
- washing and scraping are done by syringe application of pre-reduced brain heart infusion broth (PR-BHIB) . Any other appropriate anaerobic medium is useable for the washing step.
- Scraping is done with the dull edge of a sterile scalpel blade. The lumen is washed, scraped and then washed again. At this point the cecal epithelium is gently scraped off with the sharp edge of the scalpel in a scraping is preferred. However, the tissue could be cut directly into the culture medium. After scraping of the inverted intestine, the scalpel and lumen wall tip are washed again with PR-BHIB.
- This final wash is collected in a sterile vessel.
- the wash, with associated epithelial and bacterial cells is aspirated with a sterile syringe and needle, and used to inoculate into a tube of sterile PR-BHIB through a rubber septum. These tubes are incubated at 35°C for 48 hours, transferred and re-incubated for a second 48 hours.
- the culture is examined for the presence of human enteropathogens of interest such as Salmonella, E. coli and Camplyobacter species. If the culture is free of both human and animal pathogens and deemed safe, it is now ready for application or storage for later use.
- EXAMPLE 2 TEST OF BOVINE LMCES
- EFFICACY Bovine LMCES compositions are administered to new born calves about two times within approximately the first 24 hours of life.
- the culture is given orally by use of a bottle and nipple.
- Each treated calf receives about 500 ml of the LMCES, undiluted or up to about 10 timed diluted in milk at each application.
- the calves are allowed to feed as usual .
- about twenty four hours after administration each calf is given about 10 8 cells of a nalidixic acid resistant E. coli 0157 :H7 by oral gavage.
- the calves are grown in isolation chambers for about seven days to allow any transient E. coli 0157 :H7 cells to clear the intestinal tract.
- the calves are then sacrificed, the ceca aseptically removed and placed into sterile plastic bags.
- the ceca are then assayed for presecnce and level of E. coli 0157 :H7.
- the mean log number of the target pathogen per gram of ceca for the entire group is called the colonization factor (CF) .
- the ratio of the CF (untreated control/ CF (Treatment group) ) is called the protection factor (PF) .
- PF protection factor
- a healthy, approximately 1 to 6 months of age to fully mature, juvenile hog is tranquilized with a cocktail of drugs as is routinely used in the art.
- a mixture of 8mg/kg Ketaset, 6 mg/kg Telazol and 4 mg/kg Rompun was used.
- the hog is then sacrificed by bleed out.
- One cecum is asepticaly removed and placed in a sterile petri dish. The dish is then placed into a tub which is continuously being flushed with oxygen-free nitrogen gas . All manipulations must be done below the rim of the tub to keep the culture to be harvested in an anaerobic environment .
- the length of the cecum is carefully inverted on a sterile implement without touching the inside surface.
- the contents are removed by a combination of washings and scraping. Washing is done by syringe application of pre-reduced broth. Scraping is done with the dull edge of a sterile instrument . The lumen is washed, scraped, and then washed again. At this point the cecal epithelium is gently scraped with the sharp edge of a scalpel or may be cut in small sections (about 5 cm) . After scraping of the inverted cecum, the scalpel and lumen wall tip are washed again with PR-BHIB. This final wash or cecal sections is/are collected in a sterile vessel.
- the wash, with associated bacterial cells is aspirated with a sterile syringe and needle, and used to inoculate into a tube of sterile PR-BHIB through a rubber septum. These tubes are incubated at approximately 35°C for approximately 48 hours, transferred and reincubated for an approximately second 48 hours.
- the culture is examined for the presence of human enteropathogens of interest such as Salmonella, E. coli , and Campylobacter species. If the cultures is free of pathogens and deemed safe, it is ready for application or storage.
- a second dose of approximately 5 ml was administered at about 24 hours.
- Pigs were challenged with about 10 3 CFU S. choleraesuis by intranasal instillation about 48 hours post-farrowing (24 hours past the last LMCES administration) .
- the pigs are allowed to feed as usual. Rectal temperatures and rectal swabs were taken daily for about 7 days post-challenge from each pig and cultured for Salmonella . At about day 7 postchallenge, all pigs were sacrificed and necropsied.
- Tissues were collected for qualitative bacteriology and included tonsil (ton) , mandibular lymph node (min) , lung, brachiale lymph node (bin) , liver, spleen (spl) , middle ileum, ileocolic junction (icj), ileocolic lymph nodes, cecum (cec) , cecal contents (cc) , colon (col) , colonic lymph nodes, and stomach wall (sw) . Quantitative bacteriology was also conducted on the cecal contents and ileocolic junction to determine the level of Salmonella within tissues.
- sow feces was also collected and cultured prior to farrowing, within about 48 hours after farrowing and at about day 7 post-challenge of the pigs (sows were never directly challenged with S. choleraesuis) .
- Control pigs were not given LMCES but were challenged at about 48 hours of age. Tissues were collected and processed as described above.
- Controls for trails 1 and 2 did not receive any LMCES, only the challenge organism. As can be seen, there is not only reduced levels of the challenge organism but also reduced levels of the native colonization. While reduction is observed in pigs already colonized with Salmonella other than that received from the challenge, the degree of protection is reduced suggesting that in suckling pigs, an earlier administration may be warranted.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Fodder In General (AREA)
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP97911774A EP0932661A4 (en) | 1996-10-11 | 1997-10-10 | Livestock mucosal competitive exclusion culture to reduce enteropathogenic bacteria |
CA002267233A CA2267233A1 (en) | 1996-10-11 | 1997-10-10 | Livestock mucosal competitive exclusion culture to reduce enteropathogenic bacteria |
BR9712252-1A BR9712252A (en) | 1996-10-11 | 1997-10-10 | Culture of competitive exclusion of mucosa of domestic animals for reduction of enterogenic bacteria |
HU0000148A HUP0000148A3 (en) | 1996-10-11 | 1997-10-10 | Livestock mucosal competitive exclusion culture to reduce enteropathogenic bacteria |
AU49071/97A AU738730B2 (en) | 1996-10-11 | 1997-10-10 | Livestock mucosal competitive exclusion culture to reduce enteropathogenic bacteria |
JP51861398A JP2002503084A (en) | 1996-10-11 | 1997-10-10 | Competitive exclusion culture of livestock mucosa to reduce enteropathogenic bacteria |
UA99052610A UA73269C2 (en) | 1996-10-11 | 1997-10-10 | A culture of competitive exception for reducing entero pathogenic bacteria prepared from livestock mucous membrane |
PL97332621A PL189717B1 (en) | 1996-10-11 | 1997-10-10 | Competitively eliminating culture from livestock mucous membrane for reducing population of intestinally pathogenic bacteria |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/729,113 US5807546A (en) | 1996-10-11 | 1996-10-11 | Livestock mucosal competitive exclusion culture to reduce enteropathogenic bacteria |
US08/729,113 | 1996-10-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998016626A1 true WO1998016626A1 (en) | 1998-04-23 |
Family
ID=24929644
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1997/018769 WO1998016626A1 (en) | 1996-10-11 | 1997-10-10 | Livestock mucosal competitive exclusion culture to reduce enteropathogenic bacteria |
Country Status (12)
Country | Link |
---|---|
US (2) | US5807546A (en) |
EP (1) | EP0932661A4 (en) |
JP (1) | JP2002503084A (en) |
CN (2) | CN1233285A (en) |
AU (1) | AU738730B2 (en) |
BR (1) | BR9712252A (en) |
CA (1) | CA2267233A1 (en) |
CZ (1) | CZ294683B6 (en) |
HU (1) | HUP0000148A3 (en) |
PL (1) | PL189717B1 (en) |
UA (1) | UA73269C2 (en) |
WO (1) | WO1998016626A1 (en) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5951977A (en) * | 1997-10-14 | 1999-09-14 | The United States Of America, As Represented By The Secretary Of Agriculture | Competitive exclusion culture for swine |
US7820420B2 (en) * | 2000-08-11 | 2010-10-26 | Whitlock David R | Compositions including ammonia oxidizing bacteria to increase production of nitric oxide and nitric oxide precursors and methods of using same |
BR0306868A (en) * | 2002-01-11 | 2005-04-12 | David R Whitlock | Compositions including ammonia oxidizing bacteria and methods for using them |
US7323166B2 (en) | 2002-06-19 | 2008-01-29 | Board Of Regents University Of Nebraska | Lactic acid bacteria cultures that inhibit food-borne pathogens |
US20040241150A1 (en) * | 2002-12-19 | 2004-12-02 | Hargis Billy M. | Defined competitive exclusion cultures for food borne pathogens |
WO2004104175A2 (en) * | 2003-05-14 | 2004-12-02 | University Of Georgia Research Foundation, Inc. | Probiotic bacteria and methods |
CA2539974A1 (en) * | 2003-09-26 | 2005-04-07 | David R. Whitlock | Methods of using ammonia oxidizing bacteria |
US20060039899A1 (en) * | 2004-08-23 | 2006-02-23 | Winn Robert T | Animal nutritional product that increases weight gain and reduces diarrhea morbidity, mortality and severity by stimulation of natural immune response, nutritional support of immune function and supplemental nutricines and probiotics |
WO2012009712A2 (en) | 2010-07-16 | 2012-01-19 | The Board Of Trustees Of The University Of Arkansas | Methods and compositions including spore-forming bacteria for increasing the health of animals |
WO2012044984A1 (en) | 2010-09-30 | 2012-04-05 | The Board Of Trustees Of The University Of Arkansas | Methods of selecting and using therapeutic and prophylactic probiotic cultures to reduce bacterial pathogen loads |
WO2014022572A1 (en) | 2012-08-01 | 2014-02-06 | Pacific Vet Group-Usa, Inc. | Probiotic for amelioration of coccidiosis vaccine reaction |
CA2946050C (en) | 2014-04-15 | 2023-08-29 | Aobiome Llc | Ammonia-oxidizing nitrosomonas eutropha strain d23 |
US11225640B2 (en) | 2014-04-15 | 2022-01-18 | Aobiome Llc | Ammonia oxidizing bacteria for treatment of psoriasis |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5401501A (en) * | 1988-07-05 | 1995-03-28 | Micro Chemical, Inc. | Methods for maintaining and administering live probiotic as feed additives for animals |
US5451400A (en) * | 1993-03-16 | 1995-09-19 | The United States Of America As Represented By The Secretary Of Agriculture | Nucosal competitive exclusion flora |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4335107A (en) * | 1978-06-05 | 1982-06-15 | Snoeyenbos Glenn H | Mixture to protect poultry from salmonella |
FI840816A0 (en) * | 1984-03-01 | 1984-03-01 | Farmos Oy | BAKTERIEPREPARAT |
US5206015A (en) * | 1989-06-05 | 1993-04-27 | The United States Of America As Represented By The Secretary Of Agriculture | Introduction of bacteria in ovo |
US5478557A (en) * | 1992-07-29 | 1995-12-26 | The United States Of America, As Represented By The Secretary Of Agriculture | Probiotic for control of salmonella |
GB2298432B (en) * | 1995-03-03 | 1999-04-14 | Orion Yhtymae Oy | In ovo administration of a competitive exclusion culture |
-
1996
- 1996-10-11 US US08/729,113 patent/US5807546A/en not_active Expired - Fee Related
-
1997
- 1997-10-10 UA UA99052610A patent/UA73269C2/en unknown
- 1997-10-10 AU AU49071/97A patent/AU738730B2/en not_active Ceased
- 1997-10-10 CZ CZ19991200A patent/CZ294683B6/en not_active IP Right Cessation
- 1997-10-10 CN CN97198680A patent/CN1233285A/en active Pending
- 1997-10-10 BR BR9712252-1A patent/BR9712252A/en not_active Application Discontinuation
- 1997-10-10 WO PCT/US1997/018769 patent/WO1998016626A1/en not_active Application Discontinuation
- 1997-10-10 HU HU0000148A patent/HUP0000148A3/en unknown
- 1997-10-10 EP EP97911774A patent/EP0932661A4/en not_active Withdrawn
- 1997-10-10 CN CNA031077617A patent/CN1515667A/en active Pending
- 1997-10-10 CA CA002267233A patent/CA2267233A1/en not_active Abandoned
- 1997-10-10 JP JP51861398A patent/JP2002503084A/en not_active Ceased
- 1997-10-10 PL PL97332621A patent/PL189717B1/en not_active IP Right Cessation
-
1998
- 1998-06-26 US US09/105,306 patent/US6214335B1/en not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5401501A (en) * | 1988-07-05 | 1995-03-28 | Micro Chemical, Inc. | Methods for maintaining and administering live probiotic as feed additives for animals |
US5451400A (en) * | 1993-03-16 | 1995-09-19 | The United States Of America As Represented By The Secretary Of Agriculture | Nucosal competitive exclusion flora |
Non-Patent Citations (4)
Title |
---|
CHEM. MIKROBIOL. TECHNOL. LEBENSM., 1995, Vol. 17, No. 3/4, SANNI A.I., "Characteristic Properties of Lactic Acid Bacteria Isolated from the Rumen of Maradi Goats", pages 99-104. * |
JOURNAL OF APPLIED BACTERIOLOGY, 1996, Vol. 81, ASPLUND K., "Inhibition of the Growth of Yersinia Enterocolitica O:3 by the Microflora of Porcine Caecum and Ileum in an In Vitro Model", pages 217-222. * |
JOURNAL OF DAIRY SCIENCE, 1995, Vol. 78, ABE F., "Effect of Administration of Bifidobacteria and Lactic Acid Bacteria to Newborn Calves and Piglets", pages 2838-2846. * |
See also references of EP0932661A4 * |
Also Published As
Publication number | Publication date |
---|---|
CZ294683B6 (en) | 2005-02-16 |
CN1233285A (en) | 1999-10-27 |
US5807546A (en) | 1998-09-15 |
CZ120099A3 (en) | 1999-07-14 |
UA73269C2 (en) | 2005-07-15 |
EP0932661A4 (en) | 2000-08-23 |
PL189717B1 (en) | 2005-09-30 |
CN1515667A (en) | 2004-07-28 |
PL332621A1 (en) | 1999-09-27 |
JP2002503084A (en) | 2002-01-29 |
AU4907197A (en) | 1998-05-11 |
CA2267233A1 (en) | 1998-04-23 |
HUP0000148A3 (en) | 2001-09-28 |
AU738730B2 (en) | 2001-09-27 |
BR9712252A (en) | 2000-01-25 |
EP0932661A1 (en) | 1999-08-04 |
US6214335B1 (en) | 2001-04-10 |
HUP0000148A2 (en) | 2000-06-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Gharib et al. | Comparison of the effects of probiotic, organic acid and medicinal plant on Campylobacter jejuni challenged broiler chickens | |
Fuller | The importance of lactobacilli in maintaining normal microbial balance in the crop | |
Berchieri Jr et al. | The activity in the chicken alimentary tract of bacteriophages lytic for Salmonella typhimurium | |
US9861665B2 (en) | Use of UVE bacteria for growth promotion in animals | |
JP3147903B2 (en) | Mucosal competitive exclusion flora | |
JPS647049B2 (en) | ||
WO1994003195A1 (en) | Probiotic for control of salmonella | |
JP2001514868A (en) | Enterohemorrhagic E. coli in cattle by commensal bacteria. coliO157: Control of H7 | |
HUT74951A (en) | Probiotic for control of salmonella | |
US5807546A (en) | Livestock mucosal competitive exclusion culture to reduce enteropathogenic bacteria | |
JPH05500656A (en) | Bacterial preparation for poultry | |
REDUCE | Stern et al. | |
Reda et al. | Effects of the Probiotic Candidate E. faecalis-1, the Poulvac E. coli Vaccine, and their Combination on Growth Performance, Caecal Microbial Composition, Immune Response, and Protection against E. coli O78 Challenge in Broiler Chickens | |
MXPA99003314A (en) | Livestock mucosal competitive exclusion culture to reduce enteropathogenic bacteria | |
Epps | The Effect of Thymol-BD-Glucopyranoside on the Reduction of Campylobacter Species in Food-Producing Animals | |
WO2019022373A9 (en) | Novel lactobacillus having antiviral effect and composition thereof | |
Finney | Epidemiology of Non-typhoidal Salmonella in Veal Calves | |
Butler | Bovine salmonellosis | |
Ibrahim et al. | Campylobacter jejuni infection in Japanese quail (Coturnix Coturnix)“isolation, pathogenicity and public health implications” | |
EL-Moghazy et al. | Effect of probiotics and prebiotics on economic, microbial and immunological traits in local broilers’ purebreds and crossbreds chickens | |
Park | Potential factors influencing Campylobacter jejuni cecal colonization in chickens |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 97198680.0 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2267233 Country of ref document: CA Ref document number: 2267233 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: PV1999-1200 Country of ref document: CZ |
|
ENP | Entry into the national phase |
Ref document number: 1998 518613 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1997911774 Country of ref document: EP Ref document number: PA/a/1999/003314 Country of ref document: MX |
|
WWP | Wipo information: published in national office |
Ref document number: PV1999-1200 Country of ref document: CZ |
|
WWP | Wipo information: published in national office |
Ref document number: 1997911774 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWG | Wipo information: grant in national office |
Ref document number: PV1999-1200 Country of ref document: CZ |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1997911774 Country of ref document: EP |